This trial is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control (HbA1c) using NovoMix® 30 for treatment of type 1 and type 2 diabetes under normal clinical practice conditions in Romania.
Study Type
OBSERVATIONAL
Enrollment
942
Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
Unnamed facility
Bucharest, Romania
Change in HbA1c from baseline
Time frame: For the duration of the study
Percentage of subjects achieving HbA1c below 7.0% and below or equal to 6.5%
Time frame: after 12 weeks and 24 weeks of treatment
Change in FPG (glucose variability)
Time frame: after 12 weeks and 24 weeks of treatment
Change in PPG (postprandial control)
Time frame: after 12 weeks and 24 weeks of treatment
Change in insulin dose and number of injections
Time frame: at 12 weeks and 24 weeks of treatment
Change in oral antidiabetic drug therapy
Time frame: after 12 weeks and 24 weeks of treatment
Change in body weight
Time frame: at 12 weeks and 24 weeks of treatment
Change in number of hypoglycaemic events
Time frame: during 4 weeks proceeding routine visits at 12 weeks and 24 weeks of treatment
Number of adverse drug reactions (ADR)
Time frame: after 12 weeks and 24 weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.